These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34822842)

  • 1. The deubiquitinase USP28 stabilizes the expression of RecQ family helicases and maintains the viability of triple negative breast cancer cells.
    Wang J; Dong Y; Ma H; Wu L; Zhen X; Tang L; Jin J; Han S; Zhang P; Peng J
    J Biol Chem; 2022 Jan; 298(1):101443. PubMed ID: 34822842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RECQL5 plays an essential role in maintaining genome stability and viability of triple-negative breast cancer cells.
    Peng J; Tang L; Cai M; Chen H; Wong J; Zhang P
    Cancer Med; 2019 Aug; 8(10):4743-4752. PubMed ID: 31231988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFβ-Induced Breast Cancer Metastasis.
    Liu S; González-Prieto R; Zhang M; Geurink PP; Kooij R; Iyengar PV; van Dinther M; Bos E; Zhang X; Le Dévédec SE; van de Water B; Koning RI; Zhu HJ; Mesker WE; Vertegaal ACO; Ovaa H; Zhang L; Martens JWM; Ten Dijke P
    Clin Cancer Res; 2020 Mar; 26(6):1460-1473. PubMed ID: 31857432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells.
    Li J; Peng J; Wu L; Shen X; Zhen X; Zhang Y; Ma H; Xu Y; Xiong Q; Zhu Q; Zhang P
    J Biol Chem; 2023 Jul; 299(7):104856. PubMed ID: 37230388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the deubiquitinase USP28 as a novel molecular therapeutic target of ovarian cancer.
    Shen J; Xie M; Xu Y; Qian Q; Qiu T; Shi W; Ren D; Ji J; Huang J
    Biochem Biophys Res Commun; 2023 Jan; 638():184-191. PubMed ID: 36462492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
    Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
    J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer.
    Jaiswal A; Murakami K; Elia A; Shibahara Y; Done SJ; Wood SA; Donato NJ; Ohashi PS; Reedijk M
    Proc Natl Acad Sci U S A; 2021 Sep; 118(38):. PubMed ID: 34518219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers.
    Arora A; Abdel-Fatah TM; Agarwal D; Doherty R; Croteau DL; Moseley PM; Hameed K; Green A; Aleskandarany MA; Rakha EA; Patterson K; Ball G; Chan SY; Ellis IO; Bohr VA; Bryant HE; Madhusudan S
    Carcinogenesis; 2016 Jan; 37(1):63-71. PubMed ID: 26586793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deubiquitinating enzyme USP9X regulates metastasis and chemoresistance in triple-negative breast cancer by stabilizing Snail1.
    Guan T; Yang X; Liang H; Chen J; Chen Y; Zhu Y; Liu T
    J Cell Physiol; 2022 Jul; 237(7):2992-3000. PubMed ID: 35506169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dimeric deubiquitinase USP28 integrates 53BP1 and MYC functions to limit DNA damage.
    Jin C; Einig E; Xu W; Kollampally RB; Schlosser A; Flentje M; Popov N
    Nucleic Acids Res; 2024 Apr; 52(6):3011-3030. PubMed ID: 38227944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
    Bilir B; Kucuk O; Moreno CS
    J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.
    Banda M; Speyer CL; Semma SN; Osuala KO; Kounalakis N; Torres Torres KE; Barnard NJ; Kim HJ; Sloane BF; Miller FR; Goydos JS; Gorski DH
    PLoS One; 2014; 9(1):e81126. PubMed ID: 24404125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment.
    Bodenstine TM; Chandler GS; Reed DW; Margaryan NV; Gilgur A; Atkinson J; Ahmed N; Hyser M; Seftor EA; Strizzi L; Hendrix MJ
    Cell Cycle; 2016 May; 15(9):1295-302. PubMed ID: 27007464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
    Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells.
    Shanle EK; Zhao Z; Hawse J; Wisinski K; Keles S; Yuan M; Xu W
    Mol Endocrinol; 2013 Oct; 27(10):1762-75. PubMed ID: 23979844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells.
    Wu Y; Wang Y; Yang XH; Kang T; Zhao Y; Wang C; Evers BM; Zhou BP
    Cell Rep; 2013 Oct; 5(1):224-36. PubMed ID: 24075993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
    Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.
    Black JL; Harrell JC; Leisner TM; Fellmeth MJ; George SD; Reinhold D; Baker NM; Jones CD; Der CJ; Perou CM; Parise LV
    Breast Cancer Res Treat; 2015 Jul; 152(2):337-46. PubMed ID: 26105795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.